文献速递膀胱癌与上尿路尿路上皮癌

整合尿液与血浆DNA分析用于上尿路尿路上皮癌分子分期

Integrated Urine and Plasma DNA Analysis for Molecular Staging of Upper Tract Urothelial Carcinoma.
PubMed 文献 · Eur Urol Oncol · 2026-09-19

本研究纳入41例接受手术切除的局限性上尿路尿路上皮癌患者,评估尿液肿瘤DNA(utDNA)TP53突变和血浆循环肿瘤DNA(ctDNA)状态作为肌层浸润预测指标的效能。分子分期是肌层浸润的唯一显著多变量预测因子(OR 8.5,p=0.004),与标准诊断分期联用较标准风险因素显著提高特异度(70% vs 25%)和阳性预测值(74% vs 53%)。

要点

  • 分子分期(utDNA TP53和ctDNA状态)是肌层浸润的独立预测因子(OR 8.5,p=0.004)。
  • 分子分期联合标准诊断分期较标准风险因素提高特异度(70% vs 25%)和阳性预测值(74% vs 53%)。
  • 复合液体活检可无创改善UTUC分期和风险分层。

核心结论

  • 复合液体活检检测可显著改善上尿路尿路上皮癌的无创分期和预后分类。

研究设计与样本

  • 研究纳入41例接受手术切除的局限性上尿路尿路上皮癌患者,评估utDNA和ctDNA检测。

主要发现

  • 41例患者中21例(51%)为肌层浸润性上尿路尿路上皮癌。
  • 单变量逻辑回归显示分子分期预测肌层浸润的OR为9.6(p=0.002)。
  • 多变量分析中分子分期是唯一显著预测因子(OR 8.5,p=0.004)。

关键数值与推荐

  • 分子分期联合标准诊断分期识别肌层浸润的特异度为70%,标准风险因素为25%。
  • 分子分期联合标准诊断分期的阳性预测值为74%,标准风险因素为53%。
  • 两者敏感度均为81%,阴性预测值分别为78%和56%(p=0.15)。

临床怎么用

  • 液体活检可用于改善上尿路尿路上皮癌的非侵入性分期和个体化风险评估。
  • 分子分期有助于优化肌层浸润患者的新辅助化疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Current clinical risk stratification for determining neoadjuvant chemotherapy (NAC) usage in nonmetastatic upper tract urothelial carcinoma (UTUC) is frequently inaccurate. This uncertainty leads to suboptimal patient selection, often resulting in either overtreatment of low-stage disease or missed opportunities for NAC in advanced cases. This study evaluates the prognostic performance of urine tumor DNA (utDNA) and plasma circulating tumor DNA (ctDNA) testing as a tool for improving the diagnostic staging and clinical management of UTUC. METHODS: A total of 41 patients who underwent surgical extirpation for localized UTUC were evaluated using utDNA and ctDNA. Prognostic performance of utDNA and ctDNA testing was compared to standard-of-care (SOC) risk assessment and pathology at surgery. The primary analysis was validation of utDNA TP53 mutation and ctDNA status as predictors of muscle-invasive UTUC. KEY FINDINGS AND LIMITATIONS: A total of 21 (51%) patients had muscle-invasive UTUC. Univariable logistic regression identified molecular staging (utDNA TP53 and ctDNA status) as a strong predictor of muscle-invasive disease (odds ratio [OR] 9.6, p = 0.002) and the only significant predictor by multivariable analysis (OR 8.5, p = 0.004). When combined with SOC diagnostic staging (biopsy and imaging), molecular staging had significantly better specificity (70% vs 25%) and postive predictive value (74% vs 53%) compared to SOC risk factors (high-grade biopsy and cytology) for identifying muscle-invasive disease, with equivalent sensitivity (81% vs 81%) and negative predictive value (78% vs 56%, p = 0.15). CONCLUSIONS AND CLINICAL IMPLICATIONS: Composite liquid biopsy testing can significantly enhance noninvasive staging of UTUC. Improved staging and prognostic classification can improve personalized risk assessment and treatment intensification.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Pallauf M, Bronimann S, Rapiey S, et al. Integrated Urine and Plasma DNA Analysis for Molecular Staging of Upper Tract Urothelial Carcinoma. Eur Urol Oncol. 2026. PMID: 42763264. doi:10.1016/j.euo.2026.08.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。